Stock events for Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals' stock experienced a 30% drop in October 2025 following the ESMO data presentation on palazestrant. In November 2025, Olema closed a $218.5 million public offering of common stock and announced a strategic collaboration in immuno-dermatology, leading to a pre-market surge. Insiders have sold more company stock than they have bought in the past six months. In February-March 2026, the company attracted Wall Street attention with analyst upgrades and new coverage. The departure of the COO/CFO in January 2026 impacted investor sentiment. The stock has gained over 110% in the past six months and 470.55% over the past year.
Demand Seasonality affecting Olema Pharmaceuticals, Inc.’s stock price
Product demand seasonality is not a significant factor for Olema Pharmaceuticals, as its products are still in clinical development. However, December has historically been a weaker month for OLMA's share price, while February and July have often seen an uplift, attributed to investor behavior rather than product demand.
Overview of Olema Pharmaceuticals, Inc.’s business
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for women's cancers. Their lead product candidate, palazestrant (OP-1250), is in Phase 3 clinical trials for ER+/HER2- breast cancer, both as a monotherapy and in combination with other inhibitors. Additionally, Olema is developing OP-3136, a KAT6 inhibitor in Phase 1 clinical trials for ER+/HER2- metastatic breast cancer and other cancers.
OLMA’s Geographic footprint
Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, and maintains operations in Cambridge, Massachusetts.
OLMA Corporate Image Assessment
Olema Pharmaceuticals generally has a positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. Palazestrant is viewed optimistically for its potential in the ER+/HER2- breast cancer market. However, the stock drop after ESMO 2025 and the departure of the COO/CFO have affected its reputation and stock performance.
Ownership
Olema Pharmaceuticals, Inc. has high institutional ownership, ranging from approximately 91.78% to 132.15%. Major institutional owners include Bain Capital Life Sciences Investors LLC, Paradigm Biocapital Advisors LP, and Janus Henderson Group Plc. Insider ownership stands at approximately 16.36%.
